The DFCI EGFR Center’s annual patient and caregiver forum is next month. Register to attend through the link below - we hope you can join us!

IDEO Xchange: Phase III HARMONi‑6 shows ivonescimab + chemo outperformed tislelizumab + chemo in first‑line squamous NSCLC, with superior PFS and comparable safety. How practice‑changing do you consider these results?

IDEO Xchange: Given the FLAURA2 exploratory analysis showing that osimertinib plus chemo improved OS across all major poor-prognosis subgroups, how likely are you to use the combination therapy as standard first-line treatment in these populations?

IDEO Xchange: Based on results from BEAMION-1 LUNG-2 cohort 2, which showed a 77% objective response rate and 96% disease control rate in untreated HER2-mutated NSCLC, how likely are you to recommend zongertinib as initial therapy over standard chemotherapy for these patients?

Join me on August 18 & 19 to hear inspiring stories from Dana-Farber patients and donate to strike out cancer: https://t.co/sJZT3wts2m #KCANCER @TheJimmyFund Sharing progress in personalized treatment for #lungcancer @DFarberThoracic @DFEGFRcenter

Follow us at the DFCI EGFR Center for updates on emerging data from #ASCO25 @DFEGFRcenter #NSCLC #EGFR OptiTROP-Lung03: sac-TMT NeoADAURA: neoadj osi/chemo HERTHENA-Lung02: HER3-DXd vs doublet Temab-A MET ADC SACHI: osi/savolitinib MET+ Zipalertinib and BAY2927088 EGFR ex20ins+

#ASCO25 is here! Join me Monday at 8:30 AM at the Arie Crown Theater to explore the role of plasma-guided adaptive first-line chemoimmunotherapy for NSCLC, abstract #8515

I am excited to announce I will be presenting at PER’s NSCLC satellite symposium during #ASCO22 in Chicago. Join us for dinner at 6:30 pm CT and then an in-depth, expert review of NSCLC treatments and clinical trials. Register now: https://t.co/wJP6tC0u1V #LCSM #NSCLC

Kicking off #TTLC22 with a discussion of EGFR-mutant NSCLC. Great to see and discuss all the advances in the last year.

A9 We are on the way to making #lungcancer a chronic disease - seeing gains in long-term survivability and more advances to come #AskReuters #ASCO2021

A8 @DeboraBruno (abstract 9005 #ASCO21) describes lower rates of NGS testing and clinical trial enrollment among African American versus Caucasian patients, highlighting reduced access to many of the advances that we celebrate at the annual meeting #AskReuters

A7 Progress at ASCO is always inspiring. Advances in targeted therapies, immunotherapies, and early diagnosis have helped to improve 5-year survival rates for NSCLC, up by 13% in the last five years. #AskReuters #ASCO2021

A6 Progress in #EGFR exon 20ins NSCLC – a subset lacking targeted therapy options until recently. Now FDA approval of amivantamab and emerging data for exon 20 inhibitors like DZD9008, with a response rate of 48% reported by James Yang at #ASCO2021 (Abstract 9008) #AskReuters

Exactly this - many gains to be made by effective implementation of existing advances in screening and personalized treatment for all patients. #AskReuters #ASCO2021

Q3 We see the stigma in society’s attitudes towards this diagnosis and in a paucity of public and private funding compared to other common cancer diagnoses. Though lung cancer is the #1 cause of cancer mortality, funding lags that of other diseases #AskReuters

Q3 We need to bring visibility to the ‘invisible disease’ through awareness and funding campaigns. It is also important to note that up to 50% of lung cancer occurs in those who have already quit smoking and in young patients >25% will be never smokers #AskReuters #ASCO21

A2 Lung cancer screening reduces risk of dying from lung cancer, so those with a current or former history of tobacco should discuss with their doctors whether screening is right for them. This AHRQ decision aid https://t.co/yHEwDpyQW6 can help with that discussion #AskReuters

Looking forward to discussing advancements in #LungCancer at #ASCO2021 with #AskReuters

Nice #lungcancer highlights from @APassaroMD - anticipated abstracts from #ASCO2021